International law firm Bird & Bird advised Stereotaxis, a pioneering American company in surgical robotics for endovascular procedures, in connection with the signing of a definitive agreement for the acquisition of Robocath, a French company based in Rouen specialising in the development of robotic solutions dedicated to the treatment of cardiovascular and neurovascular diseases.
This acquisition strengthens Stereotaxis’ positioning as a leading platform in the endovascular space, combining its magnetic navigation technology with the mechanical robotic system developed by Robocath to offer an integrated suite of robotic solutions covering electrophysiology, interventional cardiology and neurointerventions. Stereotaxis estimates that Robocath should generate annual revenues of approximately $2 million in the first year following completion of the transaction.
Bird & Bird advised on the transaction with a team comprising partner Carole Bodin, associate Jasmine Javault and associate Pascaline Sagot for the corporate/M&A aspects as well as partner Benjamin Lichtlé and associate Bertrand Joussain for the tax aspects.
